CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

Blood

Volumn 96, Issue 6, 2000, Pages 2246-2253

  Fang, G ^a   Kim, C N ^a   Perkins, C L ^a   Ramadevi, N ^a   Winton, E ^a   Wittmann, S ^a   Bhalla, K N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CYTARABINE; CYTOCHROME C; DOXORUBICIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034665903     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.6.2246     Document Type: Article

References (48)

1. Role of the BCR-ABL oncogene in human leukemia: Fifteenth Richard and Hilda Rosenthal Foundation award lecture
2. Chronic myelogenous leukemia: Update on biology and treatment
3. BCR-ABL-medialed inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
4. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
5. Enforced expression of Bcl-x(s) induces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis
6. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
7. Activation of p65 NF-κB protein by p210(BCR-ABL) in a myeloid cell line (p210(BCR-ABL) activates p65 NF-κB)
8. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-RB
9. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-RB
10. Bcl-2 independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-x(L)
11. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
12. In vitro eradication of human Bcr/Abl-positive leukemia cells with an ABL kinase inhibitor
13. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells
14. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
15. The role of the C-terminal domain of IRBI in protein degradation and stabilization
16. Inducible expression of IκBα repressor mutants interferes with NF-B activity and HIV-1 replication in Jurkat T cells
17. Differential regulation of IRBα kinase α and β by two upstream kinases, NF-RB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1
18. Isolation and characterization of an anthracycline-resistant human leukemic cell line
19. Bcl-x(L) overexpression inhibits taxol-induced Yama protease activity and apoptosis
20. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
21. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during taxol-induced apoptosis of human AML HL-60 cells
22. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HI-60)
23. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
24. Role of glycogene synthase kinase-3 in the phosphatidylinositol 3 kinase/Akt cell survival pathway
25. 1-β-D-Arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: Improved method for detection of internucleosomal DNA fragmentation
26. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
27. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
28. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
29. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
30. Apaf-1, a human protein homologous to C. Elegans CED-4, participated in cytochrome c-dependent activation of caspase-3
31. A requirement for NF-RB activation in Bcr-Abl-mediated transformation
32. Cellular survival: A play in three Akts
33. Bad, a heterodimeric partner for Bcl-x(L) and Bcl-2, displaces Bax and promotes cell death
34. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
35. Regulation of cell death protease caspase-9 by phosphorylation
36. Suicidal tendencies: Apoptotic cell death by caspase family proteinases
37. Oncogenic Ha-Ras induced signaling activates NFRB transcriptional activity, which is required for cellular transformation
38. JNK or IKK, AP-1 or NF-RB, which are the targets for MEK kinase 1 action?
39. Activation of the lκBα kinase complex by MEKK1, a kinase of the JNK pathway
40. Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs
41. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells
42. Medical progress: Chronic myeloid leukemia (review article)
43. Death receptors: Signaling and modulation
44. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
45. Bid, a Bcl2 interacting protein mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
46. Caspase induce cy-tochrome c release from mitochondria by activating cytosolic factors
47. The role of Apaf-1, caspase-9, and Bid proteins in etoposideor pacliltaxel-induced mitochondrial events during apoptosis
48. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia (abstract)